Home Medicare Part D Tags

View the Latest: Medicare Part D

Filter

List Grid

11-20 of 472 results

  • Improving Prescription Drug Coverage: Opportunities and Challenges for Reform

    Event Date:
    Event

    Tricia Neuman, Vice President and Director of the Medicare Policy Project, testified before the Senate Finance Committee on prescription drug coverage under Medicare. The statement reviews existing sources of prescription drug coverage for Medicare beneficiaries and the importance of such coverage for this population. It reviews current approaches for improving prescription drug coverage, identifying significant areas of common ground, as well as the key decisions and challenges facing policymakers in designing a Medicare drug benefit.

  • Views of the New Medicare Drug Law – Chartpack By Income Group

    Report

    This comprehensive survey of people on Medicare, conducted in June and July 2004, assesses their attitudes toward the new Medicare drug law. This chartpack, issued in September 2004, presents additional analysis on the survey data, looking at key findings broken down by income group. Chartpack (.pdf)

  • The Facts About the $35 Insulin Copay Cap in Medicare

    Policy Watch

    This brief describes the facts about actions taken under both the Trump and Biden Administrations related to capping insulin copayments for people with Medicare and explains the differences between their approaches.

  • 10 Essential Facts About Medicare and Prescription Drug Spending

    Other Post

    Prescription drugs play an important role in medical care for 60 million seniors and people with disabilities, and account for nearly $1 out of every $5 in Medicare spending. This chart series examines trends in Medicare and beneficiary out-of-pocket spending on prescription drugs, and what the public thinks about different options for keeping drug costs down.

  • Key Facts About Medicare Drug Price Negotiation

    Issue Brief

    Under the Medicare Drug Price Negotiation Program, the federal government negotiates prices with drug companies for certain high-cost drugs covered under Medicare Part B and Part D. This brief provides information about several key aspects of the Medicare drug price negotiation program, with a focus on the 2028 implementation year.

  • Recent Trends in GLP-1 Use and Spending in Medicare

    Issue Brief

    Ahead of the Trump administration’s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare’s negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMS’s Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.

  • Poll: 1 in 8 Adults Say They’ve Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease 

    News Release

    About one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds. This includes 6% of adults who say they are currently taking one of these drugs, which include Ozempic, Wegovy and MounjaroThe shares of adults who report ever…